Supported by NIAID scientists discover cooperation with second antibody
John R. Mascola, MD, right, led a team to study the Vaccine Research Center at NIAID.
A strategy for the development of a highly effective HIV vaccine is to learn how some people infected with certain viruses naturally develop antibodies, which are capable of preventing a large proportion of HIV strains infecting human cells in the laboratory. These so-called broadly neutralizing antibodies (bNAbs) too late develop to help people infected beat the virus, but a vaccine can stimulate the immune system of uninfected people to produce bNAbs, they could protect them from HIV infection.
Researchers have studied samples Serial blood donated by a South African guy living with HIV during the following period: the 15ª week until the 4º year after exposure. The intention is to understand how the immune system of the person developed the powerful bNAb. Scientists had already observed as its bNAb had changed its original form, immature, to its final form, the most powerful in the fight against HIV, through interactions with the virus for many months. In a new research, scientists have discovered that at the beginning of the infection process, a second antibody, most common, had influenced the virus to develop a mutation that help the bNAb to develop its widely neutralizing capacity. Thus, the coevolution process antibody and HIV can involve more than one antibody, consisting of a finding that has potential implications for the development of an HIV vaccine.
The new study was led by Barton F. Haynes, MD, director of the Human Vaccine Institute, Faculty of Medicine, Duke University and researcher at the National Institute of Allergy and Infectious Diseases (NIAID, its acronym in English), which is part the National Institutes of Health (NIH) of the United States. The scientists at the Vaccine Research Center (VRC) who collaborated were led by John R. Mascola, MD, and director of the center.
F Gao et al. Cooperation of B-cell lineages in induction of HIV-1 broadly neutralizing antibodies. Cell DOI: 10.1016 / j.cell.2014.06.022 (2014).
Anthony S. Fauci, MD and director of NIAID, and John R. Mascola, MD and director of the Vaccine Research Center at NIAID, are available for clarification.
To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, firstname.lastname@example.org.
Translation: Evandro Gomide
Copyscape has not detected any matches for the current post. (675 words checked)IF you need the text to a job escolhar let us know by contact form and send a PDF for you
Digiproved: October 29 2014 14: 20: 30 UTC certified P560642Person Living with HIV.
A guy like any other, living life, who likes, going to college, even if only to lock the registration; with dreams, aspirations, fears and half a dozen are sure to be doing the right thing because if it were not, God would have sent my hunted
Editor if Seropositive Web Site Note: This second antibody may be our best hope for the future and perhaps cure or remission!